Get started
Author

Torsten Haneke

Observed name: T. Haneke
ORCID: 0000-0003-2563-1055
Observed ORCID: 0000-0003-2563-1055
OpenAlex ID: A5048895901
Transposable elements as a source of genetic innovation: expression and evolution of a family of retrotransposon-derived neogenes in mammals
2004 · Jürgen Brandt, Sabrina Schrauth, et al. · Gene · 119
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
2021 · Susanne Wingert, Uwe Reusch, et al. · mAbs · 70
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
2019 · Kristina Ellwanger, Uwe Reusch, et al. · mAbs · 66
PDF
Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities
2008 · Ralf Amstutz, Marco Wachtel, et al. · Cancer Research · 52
PDF
B Cell-Specific Deficiency for Smad2 In Vivo Leads to Defects in TGF-β-Directed IgA Switching and Changes in B Cell Fate
2006 · Jörg Klein, Wenjun Ju, et al. · The Journal of Immunology · 44
Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma
2018 · Thorsten Ross, Uwe Reusch, et al. · Blood · 30
Conditional inactivation of MLH1 in thymic and naive T-cells in mice leads to a limited incidence of lymphoblastic T-cell lymphomas
2010 · Cora Reiss, Torsten Haneke, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma
2017 · Thorsten Gantke, Uwe Reusch, et al. · Blood · 7
The Novel Bispecific Innate Cell Engager (ICE®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML
2022 · Nanni Schmitt, Jana-Julia Siegler, et al. · Blood · 6
Abstract 5659: AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies
2020 · Uwe Reusch, Michael Damrat, et al. · Cancer Research · 6
AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome
2021 · Jana-Julia Götz, Jens Pahl, et al. · Blood · 5
EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies.
2017 · Anne Kerber, Michael Kluge, et al. · Journal of Clinical Oncology · 4
P482: Novel Bispecific Innate Cell Engager Afm28 for the Treatment of Cd123 Positive Acute Myeloid Leukemia and Myelodysplastic Syndrome
2022 · J.-J. Siegler, N. Schmitt, et al. · HemaSphere · 1
Abstract 1881: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies
2021 · Jens Pahl, Gabriele Hintzen, et al. · Cancer Research · 1
Abstract 559: Preclinical characterization of the bispecific EGFR/CD16A innate immune cell engager AFM24 for the treatment of EGFR-expressing solid tumors
2019 · Michael Kluge, Uwe Reusch, et al. · Cancer Research · 1
AFM13 enhances the anti‐tumor activity of AB‐101 towards CD30+ tumors, conferring tumor growth control in vivo
2023 · J. Pahl, T. Haneke, et al. · Hematological Oncology
PDF
Abstract 559: Preclinical characterization of the bispecific EGFR/CD16A innate immune cell engager AFM24 for the treatment of EGFR-expressing solid tumors
2019 · Michael Kluge, Uwe Reusch, et al. · Immunology
Abstract 2786: Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors
2018 · Michael Kluge, Michael Tesar, et al. · Cancer Research
Abstract 3641: EGFR/CD16A TandAbs are efficacious NK-cell engagers with favorable biological properties which potently kill EGFR+ tumors with and without Ras mutation
2017 · Michael Kluge, Kristina Ellwanger, et al. · Cancer Research
Works count: 19
Citation count: 426
H-index: 7
I10-index: 7
Year
Topic
Type